EV/EBITDA Multiple: Ascendis Pharma Inc. (ASND)

Corporate company logo of ascendispharma.com (ASND)

The capitalization of Ascendis Pharma A/S (ASND) is based on the protected TransCon platform, which creates high barriers to entry for competitors in endocrinology. The change in the EV/EBITDA multiple clearly demonstrates market phases, with the value holding at 114.05. An innovative approach to the therapy of rare pathologies fosters strong brand loyalty, ensuring maximum patient retention through a unique hormone prolongation mechanism.

ASND (Ascendis Pharma AS) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 11/10/2026

ascendispharma.com (ASND) - metric breakdowns and financial figures

- market price and analyst price targets:
Price Chart Ascendis Pharma Inc.|ASND - Consensus Target
- company stock exchange capitalization indicators:
Market Capitalization Ascendis|ASND - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share Ascendis Pharma|ASND - Total Net Assets|Market Capitalization to Book Value Ratio ascendispharma.com|ASND - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Ascendis Pharma A/S|ASND - Long-Term Debt to Equity|Short-Term Debt to Equity Ascendis Pharma|ASND - Company Cumulative Debt|Debt to Book Capitalization Ratio Ascendis|ASND - Company Long-Term Debt|Company Short-Term Debts Ascendis Pharma|Quick Liquidity ascendispharma.com
- net income and valuation multiples indicators:
ASND - Net Financial Result|Expected Profit Ascendis Pharma A/S|ASND - Price to Earnings Ratio|Forward P/E Multiple Ascendis Pharma A/S|ASND - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ascendis|ASND - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Ascendis Pharma|ASND - Net earnings per share for the last 12 months|Quarterly EPS earnings growth ascendispharma.com|ASND - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Ascendis Pharma A/S
Initial company analysis:ASND (Ascendis Pharma Inc.)
Product sample of Ascendis Pharma

The investment appeal of Ascendis Pharma A/S (ASND) is based on the scalability of its patented extended-release therapies following the capital-intensive development phase. This metric compares the total enterprise value of the business with its operating profit before depreciation, taxes, and interest. By analyzing the EV/EBITDA ratio of Ascendis Pharma A/S (ASND) on GURU.Markets, an investor can identify the gap between market optimism and actual asset efficiency. The stability of this ratio confirms the company's fundamental resilience as it scales up production volumes.

Who Ascendis Pharma A/S competes with

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Madrigal Pharma MDGL|CORT - Enterprise Value to EBITDA Ratio|Rhythm Pharmaceuticals - EV/EBITDA Multiple|Company Value to EBITDA akerotx.com|MTSR (Metsera) - Enterprise Value to EBITDA Ratio|MLTX: Enterprise Value to Operating Income Before Depreciation Ratio|CRNX (Crinetics Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple NewAmsterdam Pharma Corp|EV/EBITDA Multiple SLNO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FOLD (amicusrx.com)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 89bio ETNB|Agios (AGIO) - Company Value to EBITDA|GPCR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MDXG: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RZLT: EV/EBITDA Multiple|LXRX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MBX Biosciences|Altimmune Inc (ALT) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aardvark Therapeutics Corp (AARD)|Enterprise Value to EBITDA Ratio Sagimet Biosciences Inc SGMT|EV/EBITDA Multiple BIOA (BioAge Labs, Inc.)|EV/EBITDA Multiple biomeafusion.com BMEA|QNCX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Fractyl Health Inc. GUTS|VTVT: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Agape ATP|PLUR (Pluristem Therapeutics) - EV/EBITDA Multiple|Company Value to EBITDA Synlogic Corp SYBX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lipocine (LPCN)|matinasbiopharma.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple SPRB (Spruce Biosciences)|GLTO: Enterprise Value to Operating Income Before Depreciation|Carmell Corporation - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio lumos-pharma.com LUMO|Organovo (ONVO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RDUS - Total Company Value to Operating Income Before Depreciation Ratio